Abstract
Immuno-oncological treatments have led to a paradigm shift in the treatment of many solid tumors, including head and neck cancers (HNSCC). An “elevated tail” in the survival curve of these patient populations indicates that individuals who survive for a critical initial period may hope for a lasting cure. Unfortunately, the percentage of responders is usually only around 15% for patients with metastatic HNSCC. Finding synergistic treatments that can increase the number of responders thus holds great promise to make a substantial difference.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
